CD8A and dengue disease: In contributing to the ongoing discourse on dengue vaccination strategies, Miauton and colleagues embarked on a pioneering effort to assess the safety and immunogenicity of a novel candidate: a CD8+ T-cell priming, gold nanoparticle (GNP)-based, multi-valent, synthetic peptide dengue vaccine (PepGNP-Dengue).2